Investment Thesis
Grace Therapeutics exhibits a strong balance sheet with zero debt and $18.7M in cash, but operates at a loss with negative cash flow (-$7.2M). While $100M in revenue and improving loss metrics (EPS +41.5% YoY) suggest operational progress, the company's path to profitability remains uncertain and sustainability depends on achieving operating cash flow breakeven within its ~2.6-year cash runway.
Strengths
- Fortress balance sheet: zero debt with $64.9M stockholders' equity and 14.96x current ratio provides substantial financial cushion
- Meaningful revenue base of $100M demonstrates market traction and business validation
- Improving loss metrics with 41.5% YoY EPS improvement signals operational progress toward profitability
Risks
- Operating losses of $8.1M with negative operating cash flow of $7.2M indicates company is burning cash despite revenue
- Current annual burn rate (~$7.2M) implies limited runway before cash depletion if profitability not achieved
- Pharmaceutical sector requires sustained R&D investment; uncertain timeline for achieving operating profitability and positive cash generation
Key Metrics to Watch
- Operating cash flow trend and path to breakeven - critical determinant of company viability
- Revenue growth rate and operating margin expansion toward profitability
- Cash balance depletion timeline and quarterly burn rate changes
Financial Metrics
Revenue
100.0M
Net Income
-6.6M
EPS (Diluted)
$-0.41
Free Cash Flow
-7.2M
Total Assets
68.5M
Cash
18.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-8.1%
Net Margin
-6.6%
ROE
-10.2%
ROA
-9.7%
FCF Margin
-7.2%
Balance Sheet & Liquidity
Current Ratio
14.96x
Quick Ratio
14.95x
Debt/Equity
0.00x
Debt/Assets
5.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T17:54:25.075449 |
Data as of: 2025-12-31 |
Powered by Claude AI